Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01483664 · ClinicalTrials.gov registry record
Communication Skills Intervention to Promote Transition Into Survivorship
A clinical trial of Diffuse Large B Cell Lymphoma and Hodgkin's Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- 314
- Enrollment target
- 9
- Study locations
NCT01483664: Active study of Diffuse Large B Cell Lymphoma and Hodgkin's Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01483664 is a study of Diffuse Large B Cell Lymphoma and Hodgkin's Lymphoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 314 participants, above the 216-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (45% higher). The trial reports 9 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01483664, a study of Diffuse Large B Cell Lymphoma and Hodgkin's Lymphoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 314 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to improve the communication skills of physicians who transition lymphoma cancer patients from the end of treatment to survivorship.
Conditions Studied
Study Locations (9)
New York
- Maimonides Medical Center - Brooklyn
- Memorial Sloan Kettering Cancer Center at Commack - Commack
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Cancer Center at Mercy - Rockville Centre
- Memorial Sloan Kettering Cancer Center at Phelps - Sleepy Hollow
Florida
- Tampa General Hospital - Tampa
- Moffitt Cancer Center - Tampa
New Jersey
- Memorial Sloan Kettering at Basking Ridge - Basking Ridge
Texas
- Md Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2011-11 |
| Est. Completion | 2026-11 |
What the registry record for NCT01483664 still lists
NCT01483664 is an observational study that tracks outcomes without assigning an intervention. The registered 314 participants enrollment target is mid-sized for trials with a published cap, above the 216-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (45% higher).
The record links to 2 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 0 interventions.
NCT01483664 lists 9 locations in 4 states (New York, Florida, New Jersey).
Frequently Asked Questions
What is clinical trial NCT01483664 about?
NCT01483664 is a clinical study titled "Communication Skills Intervention to Promote Transition Into Survivorship". The purpose of this study is to improve the communication skills of physicians who transition lymphoma cancer patients from the end of treatment to survivorship.
What is the current status of trial NCT01483664?
This trial is currently active not recruiting. The enrollment target is 314 participants. The study started on 2011-11. Estimated completion is 2026-11.
What conditions does trial NCT01483664 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, Hodgkin's Lymphoma.
Who is sponsoring clinical trial NCT01483664?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01483664 being conducted?
This trial has 9 study locations across Florida, New Jersey, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01483664's enrollment target sits among peer trials
314 18th of 114 higher than 97 of 114 other Diffuse Large B Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diffuse Large B Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology
RECRUITING
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
RECRUITING · Phase 2
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03866382 · 314 participants · Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- NCT04500756 · 314 participants · Phase 2
Limiting AAA With Metformin (LIMIT) Trial
- NCT06167746 · 314 participants · Phase 3
iCare4Me Transitions
- NCT06883097 · 314 participants · NA
Quitting Matters Human Immunodeficiency Virus Hybrid Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia